Quadruple Maintenance Immunosuppression in Lung Transplantation

Core Immunosuppression Components

The European Respiratory Society recommends tacrolimus as the preferred calcineurin inhibitor for maintenance immunosuppression in lung transplant recipients, with target therapeutic trough blood levels ranging from 5-15 ng/mL for adult patients once steady state is achieved 1
For patients who develop bronchiolitis obliterans syndrome (BOS) while on cyclosporine, switching to tacrolimus is recommended to mitigate lung function decline, as suggested by the European Respiratory Society 1
The European Respiratory Society advises against long-term high-dose corticosteroids (>30 mg/day of prednisone) for lung transplant recipients who develop BOS 2
Augmented immunosuppression with systemic steroids is recommended for non-minimal acute cellular rejection to prevent BOS development, according to the European Respiratory Society 3

The European Respiratory Society recommends azithromycin as a trial therapy for lung transplant recipients who develop BOS, administered at 250 mg daily for 5 days, then 250 mg three times weekly for at least 3 months 2
For non-minimal acute cellular rejection (Grade ≥A2) or lymphocytic bronchiolitis, augmented immunosuppression with systemic steroids is recommended, including intravenous methylprednisolone 1000 mg daily for 3 days, as suggested by the European Respiratory Society 4

The European Respiratory Society and the American College of Chest Physicians note that infection is a major complication of immunosuppressive therapy, with combination therapy increasing the risk for opportunistic infections 5
Regular monitoring of blood levels is essential for calcineurin inhibitors to avoid toxicities, and CBC with differential is advised for all patients receiving drugs associated with bone marrow suppression, according to the American College of Chest Physicians 5

Conventional immunosuppression does not appear to affect IgE-sensitization, which is relevant for transplant recipients with allergic conditions, as reported by the American Society of Transplantation 6
Vaccination responses may be impaired in transplant recipients on immunosuppression, according to the Infectious Diseases Society of America 7

Therapeutic drug monitoring of tacrolimus trough concentrations is required to prevent toxicity in adult lung transplant recipients receiving tacrolimus‑based maintenance therapy. 8

In recipients who develop significant gastrointestinal intolerance (e.g., diarrhea) while on mycophenolic acid, temporary interruption or dose reduction of the drug is advised to improve tolerability. 8
If a patient exhibits clinical features suggestive of progressive multifocal leukoencephalopathy while on mycophenolic acid, immediate discontinuation of the agent is recommended. 8

When sirolimus (or other mTOR inhibitors) is incorporated into the immunosuppressive regimen, regular measurement of drug concentrations is necessary to maintain therapeutic levels. 8
Prior to initiating mTOR inhibitor therapy and throughout treatment, lipid profiles (cholesterol and triglycerides) should be assessed and monitored to detect hyperlipidemia. 8
Renal function (serum creatinine) and blood pressure must be routinely evaluated in patients receiving mTOR inhibitors to identify nephrotoxicity or hypertensive effects. 8
Administration of sirolimus during the early postoperative period is contraindicated because of an increased risk of airway dehiscence. 8
In recipients with pre‑existing elevated fasting triglyceride levels, mTOR inhibitor therapy should be avoided or triglycerides should be closely monitored if the drug is used. 8
Ongoing surveillance for hyperlipidemia is required throughout mTOR inhibitor treatment to manage potential lipid abnormalities. 8
New or worsening respiratory symptoms in a patient on sirolimus should prompt evaluation for possible sirolimus‑induced pulmonary toxicity. 8